# Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study

> **NCT01089725** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 385 (actual)

## Conditions studied

- Osteoarthritis
- Arthritis
- Pain

## Interventions

- **BIOLOGICAL:** Placebo IV
- **BIOLOGICAL:** Placebo SC
- **BIOLOGICAL:** Tanezumab SC
- **BIOLOGICAL:** Placebo IV
- **BIOLOGICAL:** Tanezumab SC
- **BIOLOGICAL:** Placebo IV
- **BIOLOGICAL:** Tanezumab SC
- **BIOLOGICAL:** Placebo IV
- **BIOLOGICAL:** Tanezumab IV
- **BIOLOGICAL:** Placebo SC

## Key facts

- **NCT ID:** NCT01089725
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03-30
- **Primary completion:** 2010-11-08
- **Final completion:** 2011-02-18
- **Target enrollment:** 385 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01089725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01089725, "Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01089725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*